Peer Review History
| Original SubmissionJanuary 26, 2025 |
|---|
|
Dear Dr. Oh, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Oct 08 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Ruobing Li, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. 4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: It is my pleasure to review the manuscript entitled Targeting Anger for COVID-19 Prevention: The Motivating Role of Anger on Media Use and Vaccination Intention. This manuscript addresses a valuable topic, uses solid methods, and is clearly written. At this stage, however, I have some concerns that are listed below. 1. The research gap presented in this study is a bit vague. In page 3, line 60, the authors stated that “there is minimal scholarly attention investigating how anger and media use collectively are associated with COVID-19 vaccine behavior”. Nonetheless, I found that there are several papers addressing this issue, e.g., Ali et al., (2022); Featherstone et al., (2020); and Silar-Taut and Mican (2022). The authors may consider making a stronger case about the research gap. Ali, K., Li, C., Zain-ul-abdin, K., & Muqtadir, S. A. (2022). The effects of emotions, individual attitudes towards vaccination, and social endorsements on perceived fake news credibility and sharing motivations. Computers in Human Behavior, 134, Article 107307. https://doi.org/10.1016/j.chb.2022.107307 Featherstone, J. D., & Zhang, J. (2020). Feeling angry: The effects of vaccine misinformation and refutational messages on negative emotions and vaccination attitude. Journal of Health Communication, 25(9), 692–702. https://doi.org/10.1080/10810730.2020.1838671 Sitar-Taut, D.-A., & Mican, D. (2022). Social media exposure assessment: Influence on attitudes toward generic vaccination during the COVID-19 pandemic. Online Information Review, 47(1), 138–161. https://doi.org/10.1108/OIR-11-2021-0621 2. Page 5, line 102: The author stated that only anger can be oriented to a specific individual or entity. I don’t quite agree with the statement. For instance, fear can be directed towards a specific entity (e.g., fear towards criminals; fear towards a virus). As such, I think anger, though being a unique emotion, might not be unique in this way. The authors may clarify more about the uniqueness of anger or refrain from this and similar statements in other parts of this manuscript. 3. Page 6, lines 120-126. The argument is a bit odd for me. I concur that anger leads to increased information seeking and processing. Nonetheless, this can’t lead to the argument that investigating different types of media is important. The authors may make a stronger case about this. 4. In study 1, why social media use was measured by the frequencies while traditional media use by the number of minutes? 5. I’m a bit confused by the aim and actual methods of study 2. If the authors intend to identify the target of anger, why is there a pre-decided codebook rather than identifying the targets of anger using a bottom-up method (classifying targets based on the data using other computational methods)? 6. Page 22, line 458: A minor issue: Trump is now president. 7. In study 3, factors of anger are named anger factor 1, 2, and 3. I think more meaningful names will make the study easier to understand for readers. 8. Why are the indirect associations between the three factors of anger tested in three separate models rather than one model with three independent variables? Reviewer #2: This is a well-conceived and carefully executed project. It tackles an important issue in research about emotions – what the targets of a particular emotion are and how this affects attitudinal and behavioral outcomes. A fair amount of research has been conducted to document the experience of anger during the COVID pandemic. People may have good intuition in terms of the targets and nature of this emotional experience. However, empirical studies are extremely limited. This is one of the first studies that employed a three-study design to investigate this issue. The authors are apparently well-versed in relevant literature and methodologically versatile. The manuscript is clearly organized and accessible, and the research questions are thoughtfully derived from the reviewed literature. The findings contribute meaningfully to the scholarship on the impact of anger, especially in communication and public health. I have only one question regarding the social media data in the second study. There is a category of “Others (unspecified)” when coding the tweets for anger targets. If these are tweets with anger expressed but no obvious targets, I think it would be fine. However, there seems to be a subcategory in this group that did not express any anger, as noted on p.18, line 357. Indeed, the example provided in that paragraph does not seem to contain any reference of anger. This contradicts to what is mentioned in the codebook (in the supporting document) about this “Others” category where it says that “This category encompasses tweets where anger is expressed in relation to COVID-19 but does not specifically target any of the entities or issues outlined in categories 1-14.” Given that this category is disproportionately large (48% of the total tweets), and how large this subgroup (no anger expressed) is, I’d like to hear the authors’ thoughts on this. How much confidence can we put in the fine-tuned GPT model for identifying the anger tweets? ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Targeting Anger for COVID-19 Prevention: The Motivating Role of Anger on Media Use and Vaccination Intention PONE-D-25-00520R1 Dear Dr. Oh, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Ruobing Li, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: Thank you for authors' efforts of revise this manuscript. My comments are well addressed in this version. Reviewer #2: All my comments have been addressed. I appreciate the authors' thoughtful responses. Best of luck to them for their future research. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** |
| Formally Accepted |
|
PONE-D-25-00520R1 PLOS One Dear Dr. Oh, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Ruobing Li Academic Editor PLOS One |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .